Company Overview - OceanFirst Financial Corp. announced plans to acquire Flushing Financial Corporation in an all-stock deal valued at $579 million [1] - Following the announcement, OceanFirst Financial shares fell 7.4% to $18.15 [1] - Flushing Financial Corporation's shares also declined by 9.5% to $15.28 after the merger agreement was revealed [5] Market Movements - Profusa, Inc. shares surged 112% to $0.1445 after restructuring its senior secured convertible note [4] - Antelope Enterprise Holdings Limited rose 99% to $2.25, while Oriental Culture Holding LTD gained 68% to $0.1395 [4] - Ekso Bionics Holdings, Inc. saw a 54.3% increase to $8.43, attributed to positive investor sentiment [4] - Cemtrex, Inc. climbed 52% to $3.2118 as it returned to profitability despite a going-concern warning [4] Strategic Investments - OceanFirst Financial Corp. and Flushing Financial Corporation announced a $225 million strategic investment from Warburg Pincus as part of their merger agreement [5]

Market Overview - U.S. stock futures showed mixed performance after declines on Monday, with major indices fluctuating between gains and losses [1] - The Santa Claus rally, which started on December 24, appears to have resumed after a brief setback [1] Economic Context - President Donald Trump intensified his conflict with Federal Reserve Chair Jerome Powell, threatening legal action over alleged incompetence, raising concerns about central bank independence [2] - Investors are facing a quiet week for economic data, with markets closed on Thursday for New Year's Day [2] Treasury Yields and Market Projections - The 10-year Treasury bond yielded 4.12%, while the two-year bond was at 3.45% [3] - The CME Group's FedWatch tool indicates an 83.9% probability that the Federal Reserve will keep interest rates unchanged in January [3] Stock Performance - TEN Holdings Inc. shares rose 16.31% after announcing a $2.25 million private placement [5] - Fonar Corp. surged 24.49% following a definitive agreement for a "take private" sale [5] - Boeing Co. increased by 0.58% after receiving an $8.6 billion contract from the Pentagon [5] - Dermata Therapeutics Inc. was up 6.45% after closing a $12.4 million private placement [11] - Freeport-McMoRan Inc. rose 1.36% as copper prices reached a new record high of $12,000 [11] Sector Performance - Consumer discretionary, materials, and financials experienced the largest losses on Monday, while energy and real estate stocks closed higher [6] Analyst Insights - Comerica Wealth Management expresses cautious optimism for the U.S. economy, citing infrastructure spending, AI adoption, and resilient consumer demand as growth drivers [8] - The firm notes that recession risks remain below 30%, but inflation is expected to stay above the Federal Reserve's 2% target [8] - Investors are advised to adopt a defensive stance and consider small and micro-cap companies for potential outperformance [9]

Market Overview - U.S. stock futures showed mixed performance after declines on Monday, with major indices fluctuating between gains and losses [1] - The Santa Claus rally, which started on December 24, appears to have resumed after a brief setback [1] Economic Context - President Trump intensified his conflict with Federal Reserve Chair Jerome Powell, threatening legal action over alleged incompetence, raising concerns about central bank independence [2] - Investors are facing a quiet week for economic data, with markets closed on Thursday for New Year's Day [2] Treasury Yields and Market Projections - The 10-year Treasury bond yielded 4.12%, while the two-year bond was at 3.45% [3] - The CME Group's FedWatch tool indicates an 83.9% probability that the Federal Reserve will keep interest rates unchanged in January [3] Stock Performance Highlights - TEN Holdings Inc. shares rose 16.31% following a $2.25 million private placement at $2.27 per share [5] - Fonar Corp. surged 24.49% after announcing a definitive agreement for a "take private" sale [5] - Boeing Co. increased by 0.58% after receiving an $8.6 billion contract from the Pentagon for the F-15 Israel Program [5] - Dermata Therapeutics Inc. was up 6.45% after closing a $12.4 million private placement [11] Sector Performance - Consumer discretionary, materials, and financials experienced the largest losses on Monday, while energy and real estate stocks closed higher [6] Analyst Insights - Comerica Wealth Management expresses cautious optimism for the U.S. economy, citing infrastructure spending, AI adoption, and resilient consumer demand as growth drivers [8] - The firm notes that recession risks remain below 30%, but inflation is expected to stay above the Federal Reserve's 2% target [8] - Investors are advised to adopt a defensive stance and consider small and micro-cap companies, as well as traditional value sectors like financials [9] Upcoming Economic Data - Key economic indicators to watch include October's S&P Case-Shiller home price index and December's Chicago Business Barometer, both scheduled for release on Tuesday [10]

Group 1 - TEN Holdings Inc. announced a $2.25 million private placement of 991,000 shares at $2.27 per share, resulting in a 17% increase in shares to $1.65 in after-hours trading [1] - Fonar Corp. shares surged 24% to $18.18 after announcing a definitive agreement for a "take private" sale [1] - CapsoVision Inc. submitted its 510(k) application to the FDA for its AI-assisted module for CapsoCam Plus, leading to an 11% decline in shares to $11.58 [1] - Verastem Inc. intends to discontinue the RAMP 203 clinical study in advanced KRAS G12C-mutated non-small cell lung cancer, causing shares to fall 2.7% to $7.55 [1] - Dermata Therapeutics Inc. closed a $12.4 million private placement priced at-the-market under Nasdaq rules, with shares jumping 10.2% to $2.05 in after-hours trading [1]

Core Insights - Coeptis Therapeutics, Inc. is facing significant challenges in capital utilization and return generation within the competitive biotechnology sector [1] - The company's Return on Invested Capital (ROIC) is -91.29%, while its Weighted Average Cost of Capital (WACC) is 5.55%, leading to a negative ROIC to WACC ratio of -16.45, indicating inefficiencies in capital utilization [2] - In contrast, ZyVersa Therapeutics, Inc. demonstrates strong capital efficiency with a positive ROIC of 220.45% and a WACC of 7.54%, resulting in a favorable ROIC to WACC ratio of 29.23 [4] Company Comparisons - Cardio Diagnostics Holdings, Inc. has a ROIC of -60.70% and a WACC of 16.84%, yielding a less severe ROIC to WACC ratio of -3.60 compared to Coeptis [3] - SeaStar Medical Holding Corporation and Dermata Therapeutics, Inc. also report negative ROICs of -121.49% and -194.54%, respectively, with ROIC to WACC ratios of -7.04 and -31.71, highlighting similar challenges in generating returns above their cost of capital [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Galecto, Inc. (GLTO) has seen a remarkable increase of 726%, trading at $30.67 [3] - C3is Inc. (CISS) is up 55%, currently priced at $3.43 [3] - Spruce Biosciences, Inc. (SPRB) has risen by 41%, trading at $184.00 [3] - Lexeo Therapeutics, Inc. (LXEO) is up 32%, priced at $8.60 [3] - Bluejay Diagnostics, Inc. (BJDX) has increased by 30%, trading at $2.03 [3] - Datavault AI Inc. (DVLT) is up 24%, currently at $2.58 [3] - Diginex Limited (DGNX) has risen by 13%, trading at $22.56 [3] - Global Interactive Technologies, Inc. (GITS) is up 13%, priced at $2.55 [3] - Odyssey Marine Exploration, Inc. (OMEX) has increased by 12%, trading at $3.00 [3] - AXIL Brands, Inc. (AXIL) is up 9%, currently at $6.16 [3] Premarket Losers - Society Pass Incorporated (SOPA) has decreased by 25%, trading at $3.94 [4] - SANUWAVE Health, Inc. (SNWV) is down 18%, currently priced at $33.30 [4] - Aehr Test Systems, Inc. (AEHR) has fallen by 18%, trading at $25.95 [4] - Aether Holdings, Inc. (ATHR) is down 16%, priced at $4.55 [4] - Dermata Therapeutics, Inc. (DRMA) has decreased by 13%, trading at $4.66 [4] - Lazydays Holdings, Inc. (GORV) is down 12%, currently at $2.55 [4] - OneMedNet Corporation (ONMD) has fallen by 11%, trading at $2.26 [4] - KORE Group Holdings, Inc. (KORE) is down 10%, priced at $2.53 [4] - Biomea Fusion, Inc. (BMEA) has decreased by 10%, trading at $2.38 [4] - CPS Technologies Corporation (CPSH) is down 9%, currently at $3.40 [4]

Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

Core Insights - Dermata Therapeutics announced positive topline results from the Phase 3 trial of XYNGARI™, a once-weekly topical treatment for moderate-to-severe acne, achieving significant clinical benefits [1][4][6] - XYNGARI™ is the first product of its kind to demonstrate clinical efficacy in a Phase 3 trial, addressing a significant market need as over 30 million acne patients seek treatment annually in the U.S. [1][9] Company Overview - Dermata Therapeutics is a late-stage biotechnology company focused on treating medical skin diseases and aesthetic applications, with XYNGARI™ being its lead product candidate [10][11] - The company is headquartered in San Diego, California, and is developing XYNGARI™ from its Spongilla technology platform, which utilizes a naturally sourced freshwater sponge [10][11] Clinical Trial Details - The Phase 3 STAR-1 trial was a randomized, double-blind, placebo-controlled study involving 520 patients aged 9 and older, evaluating the efficacy, safety, and tolerability of XYNGARI™ [5] - The primary endpoints included mean changes in inflammatory and non-inflammatory lesion counts and the Investigator Global Assessment (IGA) treatment response [5] Efficacy Results - At Week 12, 29.4% of patients treated with XYNGARI™ achieved a 2-point reduction in IGA score, compared to 15.2% in the placebo group, with a p-value of less than 0.001 [6][7] - The mean change from baseline in inflammatory lesion count was -16.8 for XYNGARI™ versus -13.1 for placebo, and for non-inflammatory lesions, it was -17.3 for XYNGARI™ versus -12.4 for placebo, both with p-values less than 0.001 [6][7] Future Plans - Following the positive results from the STAR-1 trial, Dermata plans to initiate the second Phase 3 trial, STAR-2, in the second half of 2025, which will be followed by an open-label extension study [4][6] - Successful outcomes from the Phase 3 program could support a new drug application filing with the U.S. Food and Drug Administration [5][6]

Core Insights - Dermata Therapeutics is advancing its Phase 3 STAR-1 trial for XYNGARI™, a novel topical treatment for moderate-to-severe acne, with topline results expected by the end of March 2025 [1][2] Company Overview - Dermata Therapeutics is a late-stage biotechnology company focused on treating medical and aesthetic skin conditions, with its lead product candidate being XYNGARI™, derived from a freshwater sponge [8] - The company is headquartered in San Diego, California, and is also developing a second product candidate, DMT410, for needle-free delivery of botulinum toxin [8] Product Details - XYNGARI™ is designed as a once-weekly topical treatment that targets the root causes of acne through multiple mechanisms of action, including reducing inflammation and unclogging pores [3][5] - The Phase 3 STAR-1 trial enrolled 520 patients aged 9 years and older in the U.S. and Latin America, focusing on the efficacy, safety, and tolerability of XYNGARI™ [4] Market Context - Over 30 million acne patients seek treatment annually in the U.S., with a significant unmet need for effective acne therapies [7] - Acne affects approximately 85% of U.S. teenagers and can persist into adulthood, leading to social stigma and lowered self-esteem [7]